Combined effect of strontium and zoledronate on hydroxyapatite structure and bone cell responses

Biomaterials

Volumn 35, Issue 21, 2014, Pages 5619-5626

  Boanini, Elisa ^a   Torricelli, Paola ^b   Gazzano, Massimo ^c   Della Bella, Elena ^b   Fini, Milena ^b   Bigi, Adriana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

Bisphosphonates; Co cultures; Hydroxyapatite; Osteoblast; Osteoclast; Strontium

Indexed keywords

ATOMS; COHERENT SCATTERING; GENE EXPRESSION; HYDROXYAPATITE; OSTEOBLASTS; STRONTIUM;

BISPHOSPHONATES; CO-CULTURES; CRYSTALLINE DOMAINS; DIFFERENTIATION MARKERS; OSTEOBLAST PROLIFERATION; OSTEOCLAST; OSTEOCLAST PROLIFERATION; SINGLE-CRYSTALLINE PHASE;

BONE;

CRYSTALLIN; HYDROXYAPATITE; NANOCRYSTAL; STRONTIUM; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; NANOPARTICLE;

ARTICLE; BONE CELL; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; STRUCTURE ANALYSIS; CELL SURVIVAL; CHEMISTRY; COCULTURE; DRUG EFFECTS; METABOLISM; OSTEOCYTE; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DIPHOSPHONATES; DURAPATITE; HUMANS; IMIDAZOLES; NANOPARTICLES; OSTEOBLASTS; OSTEOCYTES; STRONTIUM;

EID: 84899474374     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.053     Document Type: Article

References (46)

1. Fleisch H., Russell R.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution invitro and bone resorption in tissue culture and invivo. Science 1969, 165:1262-1264.
2. Russell R.G.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
3. Giger E.V., Castagner B., Leroux J.C. Biomedical applications of bisphosphonates. JControl Release 2013, 167:175-188.
4. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
5. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
6. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. JBone Miner Res 1998, 13:581-589.
7. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108-111.
8. Stresing V., Daubiné F., Benzaid I., Mönkkönen H., Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257:16-35.
9. Liu D., Kramer S.A., Huxford-Phillips R.C., Wang S., Della Rocca J., Lin W. Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers. Chem Commun 2012, 48:2668-2670.
10. Stresing V., Fournier P.G., Bellahcène A., Benzaïd I., Mönkkönen H., Colombel M., et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis invivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011, 48:259-266.
11. Eriksen E.F., Diez-Perez A., Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 2014, 58:126-135.
12. Rizzoli R., Åkesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.
13. Favia G., Pilolli G.P., Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009, 45:406-413.
14. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49:103-110.
15. Vermeer J.A.F., Jansen I.D.C., Marthi M., Coxon F.P., McKenna C.E., Sun S., et al. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors. Bone 2013, 57:242-251.
16. Marie P.J. Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 2005, 16:S7-S10.
17. Reginster J.Y., Felsenberg D., Boonen S., Diez-Perez A., Rizzoli R., Brandi M.L., et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five year, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58(6):1687-1695.
18. Busse B., Jobke B., Hahn M., Priemel M., Niecke M., Seitz S., et al. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: matrix incorporation of strontium is accompanied by changes in mineralization and microstructure. Acta Biomater 2010, 6:4513-4521.
19. Bonnelye E., Chabadel A., Saltel F., Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption invitro. Bone 2008, 42:129-138.
20. Capuccini C., Torricelli P., Boanini E., Gazzano M., Giardino R., Bigi A. Interaction of Sr-doped hydroxyapatite nanocrystals with osteoclast and osteoblast-like cells. JBiomed Mater Res A 2009, 89A:594-600.
21. Capuccini C., Torricelli P., Sima F., Boanini E., Ristoscu C., Bracci B., et al. Strontium-substituted hydroxyapatite coatings synthesized by pulsed-laser deposition: invitro osteoblast and osteoclast response. Acta Biomater 2008, 4:1885-1893.
22. Boanini E., Torricelli P., Fini M., Bigi A. Osteopenic bone cell response tostrontium-substituted hydroxyapatite. JMater Sci Mater Med 2011, 22:2079-2088.
23. Boanini E., Torricelli P., Gazzano M., Fini M., Bigi A. The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells invitro. Biomaterials 2012, 33:722-730.
24. Tedesco E., Roveri N., Gazzano M., Falini G., Bigi A. Structural refinements of strontium substituted hydroxylapatites. Mater Sci Forum 1998, 278-281:814-819.
25. Kuljanin J., Janković I., Nedeljković J., Prstojević D., Marinković V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. JPharm Biomed Anal 2002, 28:1215-1220.
26. Bigi A., Boanini E., Capuccini C., Gazzano M. Strontium-substituted hydroxyapatite nanocrystals. Inorg Chim Acta 2007, 360:1009-1016.
27. Boanini E., Gazzano M., Bigi A. Ionic substitutions in calcium phosphates synthesized at low temperature. Acta Biomater 2010, 6:1882-1894.
28. Young R.A. Introduction to the Rietveld method. The Rietveld method 1993, 1-38. Oxford University Press, New York. R.A. Young (Ed.).
29. Wong K.L., Wong C.T., Liu W.C., Pan H.B., Fong M.K., Lam W.M., et al. Mechanical properties and invitro response of strontium-containing hydroxyapatite/polyetheretherketone composites. Biomaterials 2009, 30:3810-3817.
30. Cheer S.M., Noble S. Zoledronic acid. Drugs 2001, 61:799-806.
31. Pan B., Farrugia A.N., To L.B., Findlay D.M., Green J., Lynch K., et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). JBone Miner Res 2004, 19:147-154.
32. Pan B., To L.B., Farrugia A.N., Findlay D.M., Green J., Gronthos S., et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells invitro. Bone 2004, 34:112-123.
33. Suratwala S.J., Cho S.K., van Raalte J.J., Park S.H., Seo S.W., Chang S.S., et al. Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. JBone Jt Surg Am 2008, 90(10):2189-2196.
34. Schumacher M., Lode A., Helth A., Gelinsky M. Anovel strontium(II)-modified calcium phosphate bone cement stimulates human-bone-marrow-derived mesenchymal stem cell proliferation and osteogenic differentiation invitro. Acta Biomater 2013, 9:9547-9557.
35. Orris I.R. Inhibition of osteoblast function invitro by aminobisphosphonates. JCell Biochem 2009, 106:109-118.
36. Peng S., Liu X.S., Huang S., Li Z., Pan H., Zhen W., et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. Bone 2011, 49:1290-1298.
37. Atkins G.J., Welldon K.J., Halbout P., Findlay D.M. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009, 20:653-664.
38. Brennan T.C., Rybchyn M.S., Green W., Atwa S., Conigrave A.D., Mason R.S. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009, 157:1291-1300.
39. Rakel A., Boucher A., Ste-Marie L.G. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Ageing 2011, 6:89-99.
40. Greiner S., Kadow-Romacker A., Schmidmaier G., Wildemann B. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. JBiomed Mater Res A 2009, 91A:288-295.
41. Centrella M., Horowitz M.C., Wozney J.M., McCarthy T.L. Transforming growth factor-b gene family members and bone. Endocr Rev 1994, 15:27-39.
42. Wehrhan F., Hyckel P., Guentsch A., Nkenke E., Stockmann P., Schlegel K.A., et al. Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFβ1-signaling and increased galectin-3 expression: a histological study on biopsies. JTransl Med 2011, 9:102-112.
43. Jia J., Yao W., Amugongo S., Shahnazari M., Dai W., Lay Y.A., et al. Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model. Bone 2013, 52:424-432.
44. 1 in strontium ranelate-induced osteogenic differentiation of rat bone marrow mesenchymal stem cells. Chin J Pathophysiol 2011, 27(12):2357-2361.
45. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., Ferguson D., et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 2004, 34:57-64.
46. Oreffo R.O.C., Mundy G.R., Seyedin S.M., Bonrwald L.F. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989, 158(3):817-823.